Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
F 7.1 -3.79% -0.28
RDHL closed down 3.79 percent on Friday, April 16, 2021, on 62 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical RDHL trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.79%
Crossed Above 20 DMA Bullish -3.79%
Outside Day Range Expansion -3.79%
20 DMA Resistance Bearish 0.28%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.28%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.84%
Inside Day Range Contraction -0.84%
Older End-of-Day Signals for RDHL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 1 day ago
60 Minute Opening Range Breakdown 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Redhill Biopharma Ltd. Description

RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Autoimmune Diseases Gastrointestinal Hypertension Antibiotic Dysfunction Heart Failure Inflammatory Bowel Disease Gastroenterology Antibiotics Thin Film Abdominal Pain Nausea Crohn's Disease Migraine Proton Bacteria Headache Headaches Treatment Of Inflammatory Bowel Disease Migraine Headache Gastrointestinal Tract Helicobacter Migraine Headaches Treatment Of Hypertension Ventricular Dysfunction

Is RDHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.52
52 Week Low 6.06
Average Volume 482,245
200-Day Moving Average 8.45
50-Day Moving Average 8.24
20-Day Moving Average 7.20
10-Day Moving Average 7.09
Average True Range 0.45
ADX 19.69
+DI 17.11
-DI 21.69
Chandelier Exit (Long, 3 ATRs ) 6.75
Chandelier Exit (Short, 3 ATRs ) 7.95
Upper Bollinger Band 7.68
Lower Bollinger Band 6.73
Percent B (%b) 0.39
BandWidth 13.13
MACD Line -0.25
MACD Signal Line -0.32
MACD Histogram 0.0655
Fundamentals Value
Market Cap 265.6 Million
Num Shares 37.4 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -4.83
Price-to-Sales 6.86
Price-to-Book 11.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.64
Resistance 3 (R3) 7.65 7.48 7.55
Resistance 2 (R2) 7.48 7.34 7.48 7.52
Resistance 1 (R1) 7.29 7.26 7.21 7.28 7.49
Pivot Point 7.12 7.12 7.08 7.12 7.12
Support 1 (S1) 6.93 6.98 6.85 6.92 6.71
Support 2 (S2) 6.76 6.90 6.76 6.68
Support 3 (S3) 6.57 6.76 6.65
Support 4 (S4) 6.56